Newly developed highly selective approaches targeting the TGF-β-anchoring protein GARP or the latent TGF-β peptide LAP could be employed in pro-tumor γδ T cell-rich tumors, such as colorectal cancer, or with γδ T cell-based therapies to avoid their polarization (119, 120). This evidence concerns the gene TGFB1 and neoplasm.